Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-1401 with or without CDX-301 in Resected Melanoma
NCT02129075Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2014
- Primary completion
- Mar 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of Flt3 ligand in melanoma, sponsored by National Cancer Institute. Started Apr 2014; status: completed.
02
Drugs
Flt3 ligand
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02129075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129075.